The diseconomics of scale: How Indian pharma’s race to scale backfires on U.S. patients
Why Indian pharmaceutical companies run the risk of driving up U.S. consumer drug prices when scaling too quickly: the diseconomics of scale.
Why the U.S. looks to India as a global supply chain hub for medications
India’s pharmaceutical industry saves U.S. consumers billions, but scaling too fast is a mistake. Premature scaling through mergers and acquisitions (M&A) is not just unsustainable, it is reckless and a recipe for inefficiency, error, and rising …
The diseconomics of scale: How Indian pharma’s race to scale backfires on U.S. patients





![Why loving organizations are the secret to ending burnout in medicine [PODCAST]](https://kevinmd.com/wp-content/uploads/603e9e41-66d6-47f3-a831-f1f9c17489b3-190x100.jpeg)





![Politics and fear have replaced science in U.S. pain management [PODCAST]](https://kevinmd.com/wp-content/uploads/11c2db8f-2b20-4a4d-81cc-083ae0f47d6e-190x100.jpeg)






